PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities

1-4 of 4

• 

  RestartResume

  Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

  RestartResume

  Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

  PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities

  Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

  Prof. John Kastelein, MD

  • 

    

    Prof. John Kastelein, MD

• 

  RestartResume

  Time to reduce implementation gaps of lipid-lowering therapy

  RestartResume

  Time to reduce implementation gaps of lipid-lowering therapy

  PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities

  Time to reduce implementation gaps of lipid-lowering therapy

  Prof Kausik Ray

  • 

    

    Prof Kausik Ray

• 

  RestartResume

  Five years of PCSK9i - Lessons from practice: Which patients benefit most?

  RestartResume

  Five years of PCSK9i - Lessons from practice: Which patients benefit most?

  PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities

  Five years of PCSK9i - Lessons from practice: Which patients benefit most?

  Prof. Erik Stroes, MD

  • 

    

    Prof. Erik Stroes, MD

• 

  RestartResume

  One year after the new ESC/EAS dyslipidemia guidelines

  RestartResume

  One year after the new ESC/EAS dyslipidemia guidelines

  PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities

  One year after the new ESC/EAS dyslipidemia guidelines

  Prof. François Mach, MD

  • 

    

    Prof. François Mach, MD